ECSP14013157A - Formulaciones liofilizadas de fgf-18 - Google Patents

Formulaciones liofilizadas de fgf-18

Info

Publication number
ECSP14013157A
ECSP14013157A EC2014013157A ECSP14013157A ECSP14013157A EC SP14013157 A ECSP14013157 A EC SP14013157A EC 2014013157 A EC2014013157 A EC 2014013157A EC SP14013157 A ECSP14013157 A EC SP14013157A EC SP14013157 A ECSP14013157 A EC SP14013157A
Authority
EC
Ecuador
Prior art keywords
formulations
fgf
liofilized
cartilage
lyophilized formulations
Prior art date
Application number
EC2014013157A
Other languages
English (en)
Inventor
Rio Alessandra Del
Alessandra Cerreti
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47356563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013157(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of ECSP14013157A publication Critical patent/ECSP14013157A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere al campo de las formulaciones farmacéuticas. Más en particular, se refiere a formulaciones liofilizadas de compuesto de factor de crecimiento de fibroblastos 18 (FGF-18) y a métodos de producción de tales formulaciones. Las formulaciones liofilizadas de acuerdo con la invención son estables después del almacenamiento durante un periodo apropiado. Se pueden usar, después de reconstituir, para el tratamiento de trastornos de los cartílagos tales como osteoartritis o lesión de los cartílagos.
EC2014013157A 2011-06-17 2014-01-17 Formulaciones liofilizadas de fgf-18 ECSP14013157A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11170437 2011-06-17
US201161499216P 2011-06-21 2011-06-21

Publications (1)

Publication Number Publication Date
ECSP14013157A true ECSP14013157A (es) 2014-02-28

Family

ID=47356563

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2014013157A ECSP14013157A (es) 2011-06-17 2014-01-17 Formulaciones liofilizadas de fgf-18

Country Status (31)

Country Link
US (2) US9326944B2 (es)
EP (2) EP3056211A1 (es)
JP (1) JP5981538B2 (es)
KR (1) KR102019520B1 (es)
CN (2) CN107715104A (es)
AR (1) AR086956A1 (es)
AU (1) AU2012268987B2 (es)
BR (1) BR112013032400B1 (es)
CA (1) CA2836667C (es)
CL (1) CL2013003618A1 (es)
CO (1) CO6940377A2 (es)
CY (1) CY1117933T1 (es)
DK (1) DK2720710T3 (es)
EA (1) EA024937B1 (es)
EC (1) ECSP14013157A (es)
ES (1) ES2575732T3 (es)
HR (1) HRP20160566T1 (es)
HU (1) HUE028355T2 (es)
IL (1) IL229977A (es)
MX (1) MX338017B (es)
MY (1) MY170630A (es)
PE (1) PE20141265A1 (es)
PL (1) PL2720710T3 (es)
PT (1) PT2720710E (es)
RS (1) RS54875B1 (es)
SG (1) SG195021A1 (es)
SI (1) SI2720710T1 (es)
TW (1) TWI527590B (es)
UA (1) UA113174C2 (es)
WO (1) WO2012172072A1 (es)
ZA (1) ZA201308698B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
SG11201604972TA (en) 2013-12-24 2016-07-28 Ares Trading Sa Fgf-18 formulation in alginate/collagen hydrogels
CN107921095A (zh) * 2015-08-13 2018-04-17 默克专利有限公司 包含fgf‑18化合物的复方组合物
FI3706710T3 (fi) * 2017-11-10 2024-07-08 Novartis Ag Pitkäkestoisesti vapautuvia formulaatioita nivelensisäisiin käyttötarkoituksiin
CN109836487B (zh) * 2019-03-01 2022-06-17 重庆派金生物科技有限公司 一种人成纤维细胞生长因子18及其可溶性重组表达方法、制备方法、制剂和应用
CN112121150A (zh) * 2019-06-24 2020-12-25 杭州生物医药创新研究中心 一种成纤维细胞生长因子10冻干粉
CN113304063A (zh) * 2021-04-23 2021-08-27 四川省恩乐生物工程有限公司 一种用于肌肤美容抗衰老的组合物及其制备方法
CN118310835A (zh) * 2024-04-16 2024-07-09 杭州百凌生物科技有限公司 一种质控品冻干粉及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
GB9015824D0 (en) 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
AU716785B2 (en) * 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
IL129379A (en) 1996-10-16 2008-12-29 Zymogenetics Inc Fibroblast growth factor homologues
CN1184673A (zh) * 1996-12-13 1998-06-17 中国医科大学 Fgf粗提多肽生长因子混合物及其提取工艺
AU6411199A (en) 1998-10-13 2000-05-01 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
JP5209161B2 (ja) 1999-12-02 2013-06-12 ザイモジェネティクス， インコーポレイテッド 腺維芽細胞成長受容体−３又は−２を発現する細胞を標的化するための方法
CN1303714A (zh) * 2000-01-13 2001-07-18 重庆多泰制药有限公司 Ii型胶原蛋白口服胃溶制剂
AU2001286996A1 (en) * 2000-08-31 2002-03-13 Chiron Corporation Stabilized fgf formulations containing reducing agents
MXPA04000747A (es) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
EP1551426B1 (en) * 2002-10-07 2014-06-25 ZymoGenetics, Inc. Methods of administering fgf18
JP4607010B2 (ja) 2003-02-28 2011-01-05 中外製薬株式会社 タンパク質含有安定化製剤
CA2567309A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
JP5948627B2 (ja) * 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
DK1828239T3 (da) 2004-12-10 2011-12-19 Zymogenetics Inc FGF18-produktion i prokaryote værter
PL1962886T6 (pl) * 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stabilne formulacje białkowe
JP4729740B2 (ja) * 2006-01-11 2011-07-20 独立行政法人産業技術総合研究所 受容体特異性を変化させたミュータント増殖因子およびそれを含有する医薬組成物
SI1986612T1 (sl) 2006-02-07 2013-01-31 Shire Human Genetic Therapies, Inc. Stabilizirana spojina glukocerebrosidaze
AU2007287510B2 (en) 2006-08-25 2012-08-30 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
CN101663046B (zh) * 2007-03-30 2017-07-28 Ambrx公司 经修饰fgf‑21多肽和其用途
CN104163864B (zh) * 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
CN101181280B (zh) * 2007-11-23 2010-07-14 深圳万乐药业有限公司 吡柔比星冻干制剂及其制备方法
RS53551B1 (en) * 2007-12-21 2015-02-27 F. Hoffmann La Roche Ag ANTIBODY FORMULATION
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物

Also Published As

Publication number Publication date
CA2836667C (en) 2020-01-14
MX338017B (es) 2016-03-29
EP2720710A1 (en) 2014-04-23
KR20140041600A (ko) 2014-04-04
PL2720710T3 (pl) 2016-09-30
AU2012268987B2 (en) 2016-09-08
EP2720710B1 (en) 2016-03-23
CY1117933T1 (el) 2017-05-17
US20140121162A1 (en) 2014-05-01
PE20141265A1 (es) 2014-09-29
EP3056211A1 (en) 2016-08-17
TWI527590B (zh) 2016-04-01
IL229977A (en) 2017-01-31
TW201302217A (zh) 2013-01-16
US9326944B2 (en) 2016-05-03
MX2013014894A (es) 2014-09-01
UA113174C2 (xx) 2016-12-26
NZ617992A (en) 2015-09-25
ZA201308698B (en) 2016-02-24
US20160228374A1 (en) 2016-08-11
JP5981538B2 (ja) 2016-08-31
AR086956A1 (es) 2014-02-05
BR112013032400B1 (pt) 2021-07-20
SG195021A1 (en) 2013-12-30
WO2012172072A1 (en) 2012-12-20
EA024937B1 (ru) 2016-11-30
ES2575732T3 (es) 2016-06-30
CL2013003618A1 (es) 2014-07-04
MY170630A (en) 2019-08-21
KR102019520B1 (ko) 2019-11-04
RS54875B1 (sr) 2016-10-31
BR112013032400A2 (pt) 2016-11-22
SI2720710T1 (sl) 2016-07-29
HUE028355T2 (en) 2016-12-28
JP2014522807A (ja) 2014-09-08
DK2720710T3 (en) 2016-06-27
CA2836667A1 (en) 2012-12-20
HRP20160566T1 (hr) 2016-06-17
CO6940377A2 (es) 2014-05-09
EA201490032A1 (ru) 2014-05-30
CN103619347A (zh) 2014-03-05
CN107715104A (zh) 2018-02-23
PT2720710E (pt) 2016-06-17

Similar Documents

Publication Publication Date Title
ECSP14013157A (es) Formulaciones liofilizadas de fgf-18
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CL2017001984A1 (es) Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).(solicitud divisional 3355-2014)
ECSP15031579A (es) Lactamas Fusionadas de Arilo y Heteroarilo
AR086042A1 (es) Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
ECSP17046848A (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y osteoartritis
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
UY36118A (es) Compuestos y composiciones para inducir condrogénesis
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
UY34578A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas q ue los contienen
PE20151023A1 (es) Triazolopirazinas
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
IN2014DN09347A (es)
UY34754A (es) ?mezcla para mejora del crecimiento de las plantas?.
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные
NZ723169A (en) Fgf-18 in graft transplantation and tissue engineering procedures
UY35785A (es) Derivados de piperazina sustituidos como moduladores del transportador de la glicina-1 (glyt1)
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
CU20140033A7 (es) Derivados de pirrolopirimidina y purina